StockData

Sight Sciences vs TELA Bio

SGHT and TELA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SGHT and TELA compare

Sight Sciences is the larger company, worth 17 times as much as TELA Bio ($578M against $34.2M).

Sight Sciences grew revenue faster over the last twelve months (9.3% versus 6.1% for TELA Bio).

Sight Sciences keeps more of each dollar of sales as profit, with a net margin of −35.7% compared with −51.5% at TELA Bio.

TELA Bio scores higher on the StockData Score (5 against 4 for Sight Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSGHTTELA
Size and price
Market cap$578M$34.2M
Share price$10.49$0.762
Change, 1 year47.5%−23.7%
Change, 5 years−45.0%−93.8%
Beta (5Y)2.872.04
Employees186218
StockData Score
Total score45 (better)
Valuation score01 (better)
Growth score22
Performance score11
Health score11
Dividend score00
Valuation
P/S6.9×0.4× (better)
P/B10.9×–
FCF yield−4.0% (better)−92.4%
Fair value$3.97–
Margin of safety−164%–
Growth
Revenue growth (TTM)9.3% (better)6.1%
Revenue growth, 5Y average22.9%34.5% (better)
Profitability
Gross margin88.0% (better)67.8%
Operating margin−33.4% (better)−42.6%
Net margin−35.7% (better)−51.5%
FCF margin−28.0% (better)−39.6%
Return on equity−48.4%–
Return on invested capital−136% (better)−212%
Financial health
Debt / equity0.96–
Interest coverage−5.4×−4.9× (better)
Current ratio4.95 (better)2.99
Altman Z-score2.15 (better)−9.41
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions40.2%70.5%
Held by insiders33.1%41.0%
Insider net buying, 12 months−$2.2M$186K (better)
Short interest, % of float3.1%2.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.